Nature Study Suggests New Therapy for Gaucher Disease

Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher and maybe other lysosomal storage diseases as a possible treatment with fewer risks and lower costs than current therapies.

An international research team led by Cincinnati Children’s Hospital Medical Center, which also included investigators from … Continue reading

Share

Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products

Foundation Medicine announced the addition of new clinical markers to its FoundationOne® and FoundationOne® Heme products, which are designed to enhance oncologists’ insight into potential response to immunotherapies. This ability to determine TMB and MSI from its assays is additional to the existing comprehensive profiling of genes provided by FoundationOne … Continue reading

Share

Fractyl receives CE for duodenal mucosal resurfacing to treat metabolic diseases

Fractyl Laboratories announced that the Company’s Revita DMRTM System, used to perform minimally invasive duodenal mucosal resurfacing for the treatment of metabolic diseases (Revita DMR procedure), has received European CE Mark approval. The announcement was made during a company presentation of new data in liver disease at the 2016 International … Continue reading

Share